Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Degludec vs Glargine U300 in Hospitalized T2D Patients
NCT05036876Completed
- Sponsor
- Medanta
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of insulin degludec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Medanta. Primary endpoint: Change in mean daily blood glucose concentration at 7 days. Started Oct 2021; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05036876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036876.